Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Squizzato, Alessandro ^a   Romualdi, Erica ^a   Passamonti, Francesco ^b   Middeldorp, Saskia ^c  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; ANTICOAGULANT AGENT;

ALL CAUSE MORTALITY; BLEEDING; CARDIOVASCULAR RISK; DRUG EFFICACY; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; POLYCYTHEMIA VERA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOCYTHEMIA; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS;

ANTICOAGULANTS; ASPIRIN; HUMANS; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 84886833304     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006503.pub3     Document Type: Review

References (35)

1. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al.Efficacy and safety of low-dose aspirin in polycythaemia vera. New England Journal of Medicine 2004;350:114-24.
2. Gruppo Italiano Studio Policitemia Vera (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. British Journal of Haematology 1997;97:453-6.
3. Finelli C, Palareti G, Poggi M, Torricelli P, Vianelli N, Fiacchini M, et al.Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. Acta Haematologica 1991;85:113-8.
4. Tartaglia AP, Goldberg JD, Berck PD, Wasserman LR. Adverse effects of antiaggregant platelet therapy in the treatment of polycythaemia vera. Seminars in Hematology 1986;23:172-6.
5. Clopidogrel and Aspirin for the Treatment of Polycythemia Vera (ISCLAP). NCT00940784. http://clinicaltrials.gov last search: 26 February 2012.
6. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;2 Suppl:e89S-e119S.
7. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, et al.Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205-10.
8. Ania BJ, Suman VJ, Sobell JL, et al.Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. American Journal of Hematology 1994;47:89-93.
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002;324:71-86.
10. Campbell PJ, Green AR. Management of polycythaemia vera and essential thrombocythaemia. Hematology/Education Program of the American Society of Hematology 2005;1:201-8.
11. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. Journal of Clinical Oncology 1990;8:556-62.
12. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al.Hydroxyurea for patients with essential thrombocythaemia and high risk of thrombosis. New England Journal of Medicine 1995;332:1132-6.
13. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
14. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
15. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al.Acute leukaemia in polycythaemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70.
16. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Annals of Internal Medicine 1995;123:656-64.
17. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al.Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine 2005;353(1):33-45.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:557-60.
19. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
20. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org.
21. Landolfi R, Ciabattoni G, Pugliese F, et al.Increased thromboxane biosynthesis in patients with polycythaemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-71.
22. Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomised trial. Seminars in Thrombosis and Haemostasis 1997;23:473-8.
23. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. British Medical Journal 2006;333:597-600.
24. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. American Journal of Epidemiology 1987;126:161-9.
25. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al.Vascular and neoplastic risk in a large cohort of patients with polycythaemia vera. Journal of Clinical Oncology 2005;23:2224-32.
26. Mesa RA, Silverstein MN, Jacobsen SJ, et al.Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. American Journal of Hematology 1999;61:10-15.
27. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Curr Opin Hematol 2011;18:105-110.
28. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
29. Passamonti F, Rumi E, Pungolino E, et al.Life expectancy and prognostic factors for survival in patients with polycythaemia vera and essential thrombocythaemia. American Journal of Medicine 2004;117:755-61.
30. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.. J Clin Epidemiol 2009;62:1006-12.
31. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagan: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
32. Rocca B, Ciabattoni G, Tartaglione R, et al.Increased thromboxane biosynthesis in essential thrombocythaemia. Thrombosis and Haemostasis 1995;74:1225-30.
33. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011].. The Cochrane Collaboration, 2011 www.cochrane-handbook.org.
34. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
35. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008, issue 2. [DOI: 10.1002/14651858.CD006503.pub2;: CD006503].